Exome Asset Management’s Gossamer Bio GOSS Stock Holding History

Exome Asset Management’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100,000	Closed	-$47.5K	–	73
2025 Q1	$47.5K	Buy	+100,000	New	+$116K	0.04%	55

Other funds holding GOSS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Exome Asset Management's GOSS Position: Q1 2026 in Review

Exome Asset Management sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 451,699 shares — an estimated $1.4M sold.

Exome Asset Management first reported a position in GOSS in Q2 2024 and held it in 7 quarters. The position peaked at $1.4M in Q4 2025. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

Exome Asset Management reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
Exome Asset Management sold 451,699 Gossamer Bio shares in Q1 2026, an estimated $1.4M.
Exome Asset Management first reported a position in Gossamer Bio in Q2 2024 and held it in 7 quarters.
Exome Asset Management's Gossamer Bio position peaked at $1.4M in Q4 2025.
184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.